BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31030473)

  • 21. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition.
    Gaggianesi M; Turdo A; Chinnici A; Lipari E; Apuzzo T; Benfante A; Sperduti I; Di Franco S; Meraviglia S; Lo Presti E; Dieli F; Caputo V; Militello G; Vieni S; Stassi G; Todaro M
    Cancer Res; 2017 Jun; 77(12):3268-3279. PubMed ID: 28400477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
    Hanna A; Nixon MJ; Estrada MV; Sanchez V; Sheng Q; Opalenik SR; Toren AL; Bauer J; Owens P; Mason FM; Cook RS; Sanders ME; Arteaga CL; Balko JM
    Breast Cancer Res; 2022 Jul; 24(1):51. PubMed ID: 35850776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.
    Zhang R; Wang G; Zhang PF; Zhang J; Huang YX; Lu YM; Da W; Sun Q; Zhu JS
    J Cell Mol Med; 2017 Jun; 21(6):1117-1127. PubMed ID: 27957827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
    Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy.
    Rudas M; Filipits M; Taucher S; Stranzl T; Steger GG; Jakesz R; Pirker R; Pohl G
    Breast Cancer Res Treat; 2003 Sep; 81(2):149-57. PubMed ID: 14572157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
    Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
    Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired Dual-Specificity Protein Phosphatase DUSP4 Reduces Corticosteroid Sensitivity.
    Kobayashi Y; Ito K; Kanda A; Tomoda K; Mercado N; Barnes PJ
    Mol Pharmacol; 2017 May; 91(5):475-481. PubMed ID: 28283554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
    Wang B; Fu JF; Hong ZW
    Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigating the Role of DUSP4 in Uveal Melanoma.
    Aughton K; Sabat-Pospiech D; Barlow S; Coupland SE; Kalirai H
    Transl Vis Sci Technol; 2022 Dec; 11(12):13. PubMed ID: 36576731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.
    Baglia ML; Cai Q; Zheng Y; Wu J; Su Y; Ye F; Bao PP; Cai H; Zhao Z; Balko J; Zheng W; Lu W; Shu XO
    Breast Cancer Res Treat; 2014 Nov; 148(1):211-20. PubMed ID: 25281216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of neoadjuvant chemotherapy in breast cancer patients].
    Zhang B; Zhang Q; Zhao L; Long F; Li S; Jiang DQ; Xu H
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):867-70. PubMed ID: 17416014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
    Loibl S; von Minckwitz G; Raab G; Blohmer JU; Dan Costa S; Gerber B; Eidtmann H; Petrich S; Hilfrich J; Jackisch C; du Bois A; Kaufmann M
    Ann Surg Oncol; 2006 Nov; 13(11):1434-42. PubMed ID: 16983592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
    Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
    Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer.
    Götte M; Kersting C; Ruggiero M; Tio J; Tulusan AH; Kiesel L; Wülfing P
    Anticancer Res; 2006; 26(1B):621-7. PubMed ID: 16739330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
    Zhou X
    Clin Breast Cancer; 2014 Apr; 14(2):e33-40. PubMed ID: 24393851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.